Objective Coronavirus disease 2019 (COVID-19) is a major challenge facing the world. Certain guidelines issued by National Health Commission of the People’s Repubilic of China recommend intravenous immunoglobulin (IVIG) for adjuvant treatment of COVID-19. However, there is a lack of clinical evidence to support the use of IVIG. Methods This single-center retrospective cohort study included all adult patients with laboratory-confirmed severe COVID-19 in the Respiratory and Critical Care Unit of Dabie Mountain Regional Medical Center, China. Patient information, including demographic data, laboratory indicators, the use of glucocorticoids and IVIG, hospital mortality, the application of mechanical ventilation, and the length of hospital stay was collected. The primary outcome was the composite end point, including death and the use of mechanical ventilation. The secondary outcome was the length of hospital stay. Results Of the 285 patients with confirmed COVID-19, 113 severely ill patients were included in this study. Compared to the non-IVIG group, more patients in the IVIG group reached the composite end point [12 (25.5%) vs 5 (7.6%), P = 0.008] and had longer hospital stay periods [23.0 (19.0–31.0) vs 16.0 (13.8–22.0), P < 0.001]. After adjusting for confounding factors, differences in primary outcomes between the two groups were not statistically significant ( P = 0.167), however, patients in the IVIG group had longer hospital stay periods ( P = 0.041). Conclusion Adjuvant therapy with IVIG did not improve in-hospital mortality rates or the need for mechanical ventilation in severe COVID-19 patients. Our study does not support the use of immunoglobulin in patients with severe COVID-19 patients.
【저자키워드】 COVID-19, SARS-CoV-2, Mortality, mechanical ventilation, IVIG, Hospital length of stay, 【초록키워드】 Treatment, coronavirus disease, Glucocorticoids, Coronavirus disease 2019, Intravenous immunoglobulin, severe COVID-19, mechanical ventilation, hospital, glucocorticoid, IVIG, Laboratory, China, Hospital mortality, Immunoglobulin, Patient, death, respiratory, in-hospital mortality, Hospital stay, adjuvant therapy, patient information, Support, retrospective cohort study, Primary outcome, two groups, in-hospital mortality rate, demographic data, Primary outcomes, severe COVID-19 patients, single-center, center, secondary outcome, end point, confounding factors, clinical evidence, unit, National Health Commission, laboratory-confirmed, Regional, objective, IMPROVE, Result, lack, was collected, reached, two group, Mountain, statistically significant, severely ill patient, 【제목키워드】 therapy, retrospective cohort study, single-center,